hey it’s tim… you’re not on my list?

Vertex Pharmaceuticals jumps in premarket trading after announcing positive results for numeric pain drug.‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Good morning Wake-Up Watchlisters! While you're sippin coffee you'll see stock futures were up on Wednesday ahead of the Federal Reserve's last announcement of the year. Investors will be focusing primarily on the Fed's policy decision due this afternoon. As of now, the sentiment is the Fed will pause rate hikes. While volatility in the markets is expected today, the truth is there are still ways to find consistent profits no matter what the Fed does. Every Wednesday our Head Trading Tactician Bryan Bottarelli uses a unique trading strategy that takes advantage of a specific market trend. Right now he's guaranteeing an 80% win rate on this weekly trade. Click here to unlock Bryan's latest pick. Here's a look at the top-moving stocks this morning. Vertex Pharmaceuticals (Nasdaq: VRTX) Vertex Pharmaceuticals is up 7.02% premarket after announcing positive results from its Phase 2 dose-ranging study of its new drug VX-548 to treat numeric pain. The study showed treatment with doses of VX-548 resulted in statistically significant and clinically meaningful reduction in the Numeric Pain Rating Scale at Week 12. Cava Group (NYSE: CAVA) Cava Group is up 1.16% premarket after its IPO expiration allowed insiders to sell shares. Roughly 13.6 million shares were traded on Tuesday, which is almost 10 times its normal trading volume. The fact that the stock is up shows buyers still outnumber sellers. We Could Be Less Than 3 Months Away From an AI Super-Event According to one of the world's top AI scientists, there's a major event coming in as little as three months that could cause expensive tech stocks like Microsoft, Google and Nvidia to double or triple in price in the following months. But whatever you do, don't go all-in on Big Tech before you have all the details. Click here. Pfizer Inc. (NYSE: PFE) Pfizer is down 7.17% in premarket trading after a weak revenue forecast hurt its shares. The U.S. drugmaker expects its annual revenue to be in the range of $58.5 billion to $61.5 billion compared with analysts' average estimate of $63.17 billion, according to LSEG data. A drop in annual vaccination rates have forced the company to launch a program in October to cut jobs and save at least $4 billion in a year. Moderna (Nasdaq: MRNA) Moderna is down 4.22% in premarket trading after announcing Chief Commercial Officer Arpa Garay will step down, after joining the company in April 2022. CEO Stephane Bancel will assume Garay's responsibilities. Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move He started from nothing and became a multimillionaire... He's now one of the most sought-after trading experts... Yet he operates 858 miles from Wall Street. And now, he's revealing his No. 1 favorite strategy that targets MASSIVE weekly profits with just one stock ticker. SEE THE PROOF HERE Monument Traders Alliance   You are receiving this email because you subscribed to Trade of the Day Wake-Up Watchlist. To unsubscribe from Trade of the Day Wake-Up Watchlist, click here. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Trade of the Day | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 1.800.507.1399 | International: +1.443.353.4977 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Trade of the Day. © 2023 Monument Traders Alliance, LLC | All Rights Reserved Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Monument Traders Alliance, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.